Advertisement

Topics

Use of Heterodimeric IL-15 in Adoptive Cell Transfer

20:00 EDT 27 Jun 2017 | NIH

Adoptive cell transfer (ACT) is a promising immunotherapeutic approach for cancer treatment. During ACT, if a patient is subjected to lymphodepletion prior to cell transfer, there is an observed improvement in a patient’s response to treatment. However, lymphodepletion is associated with detrimental effects, including severe immune dysfunction that persists after treatment.

Researchers at the National Cancer Institute (NCI) have developed a technology that provides formulations and dosage protocols for administration of hetIL-15 to replace lymphodepletion in ACT. Administration of hetIL-15 may not only replace lymphodepletion in ACT, it may also increase ACT efficiency due to its ability to increase lymphocyte growth, differentiation, and tumor entry. NCI’s technology provides specific dosage and treatment schedules of hetIL-15 to improve tumor entry and increase and maintain the number of tumor-specific lymphocytes in the tumor with an acceptable toxicity profile. Therefore, administration of hetIL-15 with ACT can replace lymphodepletion in cancer immunotherapy protocols. Thus, the NCI’s cancer immunotherapeutic protocol replicates the advantages of lymphodepletion preconditioning of the host for successful ACT while avoiding the adverse effects associated with lymphodepletion.

IC: 
NCI
NIH Ref. No.: 
E-132-2016/2
Advantages: 
  • Allows Adoptive Cell Transfer (ACT) or CAR T-cell therapy without lymphodepleting treatment
  • May support engraftment, function and maintenance of ACT cells administered with or without prior lymphodepletion
Applications: 
  • CAR T-cell therapy
  • Adoptive transfer of lymphocytes
Provider Technology ID: 
3141
Updated On: 
Jun 28, 2017
Provider Classifications: 
Date Published: 
Wednesday, June 28, 2017
Publications: 
Patent Application: 
PCT/US2017/026447
Patent Authority: 
PCT
Licensing Contacts: 
Lead Inventor: 
Inventor IC: 
NCI
NCI
NCI
Inventor Lab URL: 
http://irp.nih.gov/pi/george-pavlakis
http://irp.nih.gov/pi/barbara-felber
LPM FIrst Name: 
Rose
LPM Last Name: 
Freel
LPM Address: 
8490 Progress Drive, Riverside 5, Suite 400
LPM City: 
Frederick
Inv Is lead: 
LPM Zip: 
21701
LPM State: 
MD
LPM Phone: 
301-624-1257
LPM Suffix: 
Ph.D.
LPM Organization: 
NIH Office of Technology Transfer
LPM Fax: 
301-631-3027
DTDT Classification: 
Therapeutics
Cancer
DTDT Description: 
Cancer - Therapeutics
Cancer
Pat Filing Date: 
2017-04-06
Publication Link: 
https://www.ncbi.nlm.nih.gov/pubmed/27986749
http://dx.doi.org/10.1158/1538-7445.AM2016-LB-088
Publication Caption: 
PMID 27986749
Cancer Res 2016;76(14 Suppl):Abstract nr LB-088.
Publication Title: 

Ng SSM, et al.

Ng S, et al. Heterodimeric IL-15 enhances tumor infiltration, persistence and effector functions of adoptively transferred tumor-specific T cells in the absence of lymphodepletion. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA.

Disease Area Term: 
Collaboration Sought: 
Yes
Institute or Center: 
Collaboration Opportunity: 

Researchers at the NCI seek licensing and/or co-development research collaborations for methods of performing adoptive cell transfer by administering a heterodimeric IL-15/IL-15 receptor alpha complex (hetIL-15) in the absence of lymphodepletion.

Related Patents: 
8,871,191
9,303,080
Related Patent Publish Date: 
1281675600
1329199200
1413176400
1491886800
1168581600
1217307600
1434344400
1434344400
Related Patent Application: 

PCT/US2010/045511

13/390,504

14/512,913

15/485,093

PCT/US2007/000774

12/160,263

14/739,796

14/740,043

Related Patent Authority: 
PCT
US
US
US
PCT
US
US
US
Related Invention: 
E-254-2005/2
E-257-2009/1
E Number Only: 
E-132-2016
Inventor First Name: 
George
Barbara
Christina
Inventor Last Name: 
Pavlakis
Felber
Bergamaschi

Original Article: Use of Heterodimeric IL-15 in Adoptive Cell Transfer

NEXT ARTICLE

More From BioPortfolio on "Use of Heterodimeric IL-15 in Adoptive Cell Transfer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...